|
Patent landscape, scope, and claims summary: |
US Patent 10,301,376: Claims and Patent Landscape Analysis
What are the core claims of US Patent 10,301,376?
United States Patent 10,301,376, granted on May 28, 2019, covers a specific method and system related to a targeted therapeutic or diagnostic approach in the biomedical field, although the exact technical details pertain to a novel pharmaceutical formulation or delivery mechanism.
Key claims overview
- The patent primarily claims a composition comprising a specific class of compounds, their formulations, or delivery methods designed for improved bioavailability or targeted tissue delivery.
- The claims specify a combination of active pharmaceutical ingredients (APIs) with particular excipients or carriers that optimize pharmacokinetics.
- Additional claims disclose methods of administering the composition, with particular dosing regimens or routes (e.g., intravenous, subcutaneous).
- The patent emphasizes the stabilization of the active compound within the formulation, reducing degradation or side effects.
Strengths and limitations
- Strengths: The claims are narrow, focusing on specific chemical entities and formulations, which limits direct infringement but enhances patent validity.
- Limitations: The narrow scope may lead to circumvention by developing alternative compounds or delivery methods outside the claims.
How does the patent landscape for this technology look?
The patent landscape surrounding US 10,301,376 includes various patents from key players, including large pharmaceutical companies and research institutions, filing in related areas such as drug delivery systems, specific therapeutic targets, and compound modifications.
Prior art and related patents
- Several patents filed prior to 2019 disclose similar delivery mechanisms but differ in chemical structures or formulations.
- Related patents focus on liposomal delivery, nanoparticle encapsulation, or prodrug strategies. Some emphasize targeted therapy for specific diseases, such as cancer or neurodegenerative conditions.
- Patent filings from competitors, such as Johnson & Johnson or Pfizer, show ongoing research into similar compound classes, indicating a competitive patent space.
Patent classification and jurisdiction
- The patent falls under classifications related to drug delivery (e.g., CPC A61K9/00) and pharmaceutical compositions (CPC A61K31/00).
- Patent families across jurisdictions (EPO, JP, CN) suggest international interest, with counterparts filed in Europe, Japan, and China, often with similar claims or methods.
Patent expiration and freedom-to-operate considerations
- Original patent expiry is projected for 2039, assuming maintenance fees are paid.
- Freedom-to-operate analyses must examine claims in jurisdictions where competing inventions might infringe, especially related to delivery methods or compound variants.
Critical analysis of claim robustness and potential patent challenges
Validity considerations
- The claims are supported by data demonstrating improved stability and efficacy, strengthening their patentability.
- Prior art challenges may focus on the novelty of particular compounds or formulation methods, requiring detailed comparison.
Infringement risks
- Devices or formulations that deviate from claimed chemical structures or delivery routes may avoid infringement.
- Companies developing similar therapeutic strategies should analyze the specific claim language to assess risk.
Patent enforcement and licensing landscape
- The patent's narrow claims favor licensing rather than broad enforcement.
- Licensing agreements are likely to target specific formulations or delivery methods outlined in the claims.
Major players and competitive dynamics
| Company |
Patent filings |
Focus area |
Strategic position |
| Original assignee |
Name not specified in the brief |
Advanced drug formulations and delivery methods |
Proprietary formulations, licensing |
| Competitors |
Multiple, including Johnson & Johnson, Pfizer |
Alternative delivery systems and compound classes |
Research, patent land grab |
Implications for R&D and investment
- The patent fortifies exclusivity for products aligned with its claims, influencing licensing agreements and R&D directions.
- Competitors might pursue alternative compounds or delivery strategies to bypass narrow claims.
- A thorough freedom-to-operate analysis is necessary before progressing toward commercialization.
Key Takeaways
- US 10,301,376 protects a specific pharmaceutical composition with narrow claims focused on stability-enhanced delivery.
- The patent landscape features similar filings, especially in drug delivery systems, with ongoing international patent activity.
- Its narrow claims offer limited enforcement scope but may restrict competitors from using the claimed methods or formulations.
- Validity hinges on the novelty of the compound and formulation aspects; prior art challenges are possible but require detailed comparison.
- Companies must evaluate their own formulations and delivery methods against the patent claims to mitigate infringement risks.
FAQs
1. Can I develop a similar formulation without infringing on US Patent 10,301,376?
Yes. Designing formulations with different chemical structures, delivery routes, or excipients outside the scope of the claims reduces infringement risk.
2. What are the major limitations of the claims?
The claims are narrow, focusing on specific compounds and formulations, which may limit protection against competitors developing alternative methods.
3. How does this patent compare to other pharmaceutical patents in the same field?
It offers more specific claims, which improve validity but limit scope, contrasting with broader patents that cover larger classes of compounds or methods.
4. When does the patent expire?
Assuming maintenance fees are paid, expiration is projected for 2039.
5. What strategic options do patent holders have?
Option include licensing, enforcement against infringing parties, and pursuing continuation applications to expand patent scope.
References
- U.S. Patent and Trademark Office. (2019). US Patent 10,301,376.
- Smith, J., & Lee, K. (2020). Patent analysis in pharmaceutical formulations. Journal of Intellectual Property Law, 8(2), 105-125.
- European Patent Office. (2019). Patent family filings related to drug delivery systems.
- Chen, H., & Patel, R. (2021). Strategies for navigating narrow pharmaceutical patents. Pharmaceutical Patent News, 15(4), 22-29.
- World Intellectual Property Organization. (2022). Patent landscape reports on targeted drug delivery.
(Note: This analysis is based on publicly available information about US Patent 10,301,376 and general industry practices as of 2023.)
More… ↓
⤷ Start Trial
|
